Tenax Therapeutics (TENX) Accounts Payables (2016 - 2017)

Tenax Therapeutics' Accounts Payables history spans 6 years, with the latest figure at $579386.0 for Q3 2017.

  • For Q3 2017, Accounts Payables fell 58.39% year-over-year to $579386.0; the TTM value through Sep 2017 reached $579386.0, down 58.39%, while the annual FY2016 figure was $727599.0, N/A changed from the prior year.
  • Accounts Payables for Q3 2017 was $579386.0 at Tenax Therapeutics, up from $434195.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $1.5 million in Q2 2016 and bottomed at $434195.0 in Q2 2017.
  • The 4-year median for Accounts Payables is $890081.0 (2013), against an average of $980043.1.
  • The largest annual shift saw Accounts Payables grew 24.19% in 2013 before it crashed 71.46% in 2017.
  • A 4-year view of Accounts Payables shows it stood at $807679.0 in 2013, then rose by 20.4% to $972483.0 in 2015, then dropped by 25.18% to $727599.0 in 2016, then fell by 20.37% to $579386.0 in 2017.
  • Per Business Quant, the three most recent readings for TENX's Accounts Payables are $579386.0 (Q3 2017), $434195.0 (Q2 2017), and $1.4 million (Q1 2017).